(SLP) Simulations Plus - Ratings and Ratios
Software, Services, Simulation, AI, ADMET
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 66.0% |
| Value at Risk 5%th | 81.6% |
| Relative Tail Risk | -24.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.26 |
| Alpha | -45.79 |
| CAGR/Max DD | -0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.438 |
| Beta | 0.715 |
| Beta Downside | -0.147 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.66% |
| Mean DD | 31.02% |
| Median DD | 26.91% |
Description: SLP Simulations Plus December 26, 2025
Simulations Plus Inc. (NASDAQ: SLP) creates specialized software that models and simulates drug discovery and development processes, leveraging AI/ML to predict molecular properties. The firm operates through two segments-Software and Services-offering a portfolio that includes GastroPlus (human and animal PK/PD prediction), DDDPlus, MembranePlus, and a suite of mechanistic models such as DILIsym, NAFLDsym, and MITOsym, among others.
Its product line also features an ADMET predictor that ingests molecular structures to forecast absorption, distribution, metabolism, excretion, and toxicity, as well as MedChem Designer and the MonolixSuite for population pharmacokinetic/pharmacodynamic modeling, rapid clinical-trial analysis, and regulatory submission support. Consulting services round out the offering, covering exposure-response analyses, clinical-trial simulations, data programming, and technical writing for pharma, biotech, agro-chemical, cosmetics, food companies, academia, and regulators.
From a financial perspective, SLP reported FY 2023 revenue of roughly $78 million, reflecting a year-over-year growth rate of about 23%, while R&D expenses remained near 15% of revenue-indicative of continued investment in expanding its AI-driven capabilities. The broader health-care-technology market for drug-discovery software is projected to exceed $5 billion by 2028, driven by increasing regulatory demands for early ADMET assessment and the industry’s accelerating adoption of machine-learning models.
Given these dynamics, analysts looking for a data-rich, high-growth niche may find ValueRay’s coverage of SLP a useful next step for deeper quantitative insight.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-65.6m TTM) > 0 and > 6% of Revenue (6% = 4.66m TTM) |
| FCFTA 0.18 (>2.0%) and ΔFCFTA 13.50pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 57.68% (prev 41.19%; Δ 16.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 25.0m > Net Income -65.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (20.1m) change vs 12m ago -0.63% (target <= -2.0% for YES) |
| Gross Margin 58.99% (prev 58.47%; Δ 0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.26% (prev 37.80%; Δ 9.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -93.29 (EBITDA TTM -63.6m / Interest Expense TTM -745.0k) >= 6 (WARN >= 3) |
Altman Z'' -6.55
| (A) 0.34 = (Total Current Assets 51.5m - Total Current Liabilities 6.72m) / Total Assets 131.9m |
| (B) -0.26 = Retained Earnings (Balance) -34.4m / Total Assets 131.9m |
| (C) -0.42 = EBIT TTM -69.5m / Avg Total Assets 164.4m |
| (D) -4.85 = Book Value of Equity -34.6m / Total Liabilities 7.13m |
| Total Rating: -6.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.71
| 1. Piotroski 4.0pt |
| 2. FCF Yield 6.61% |
| 3. FCF Margin 30.33% |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.48 |
| 6. ROIC - WACC (= -52.93)% |
| 7. RoE -46.62% |
| 8. Rev. Trend 74.81% |
| 9. EPS Trend -30.63% |
What is the price of SLP shares?
Over the past week, the price has changed by +3.11%, over one month by +2.26%, over three months by +28.78% and over the past year by -31.25%.
Is SLP a buy, sell or hold?
- Strong Buy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SLP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.3 | 12.4% |
| Analysts Target Price | 22.3 | 12.4% |
| ValueRay Target Price | 18.5 | -6.9% |
SLP Fundamental Data Overview January 08, 2026
P/S = 4.9031
P/B = 3.1124
P/EG = 9.7712
Beta = 1.095
Revenue TTM = 77.7m USD
EBIT TTM = -69.5m USD
EBITDA TTM = -63.6m USD
Long Term Debt = 616.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 412.0k USD (from shortTermDebt, last quarter)
Debt = 616.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -30.2m USD (from netDebt column, last quarter)
Enterprise Value = 356.5m USD (388.2m + Debt 616.0k - CCE 32.4m)
Interest Coverage Ratio = -93.29 (Ebit TTM -69.5m / Interest Expense TTM -745.0k)
EV/FCF = 15.13x (Enterprise Value 356.5m / FCF TTM 23.6m)
FCF Yield = 6.61% (FCF TTM 23.6m / Enterprise Value 356.5m)
FCF Margin = 30.33% (FCF TTM 23.6m / Revenue TTM 77.7m)
Net Margin = -84.42% (Net Income TTM -65.6m / Revenue TTM 77.7m)
Gross Margin = 58.99% ((Revenue TTM 77.7m - Cost of Revenue TTM 31.9m) / Revenue TTM)
Gross Margin QoQ = 56.38% (prev 56.38%)
Tobins Q-Ratio = 2.70 (Enterprise Value 356.5m / Total Assets 131.9m)
Interest Expense / Debt = 119.3% (Interest Expense 734.8k / Debt 616.0k)
Taxrate = 6.72% (-4.66m / -69.4m)
NOPAT = -64.8m (EBIT -69.5m * (1 - 6.72%)) [loss with tax shield]
Current Ratio = 7.67 (Total Current Assets 51.5m / Total Current Liabilities 6.72m)
Debt / Equity = 0.00 (Debt 616.0k / totalStockholderEquity, last quarter 124.8m)
Debt / EBITDA = 0.48 (negative EBITDA) (Net Debt -30.2m / EBITDA -63.6m)
Debt / FCF = -1.28 (Net Debt -30.2m / FCF TTM 23.6m)
Total Stockholder Equity = 140.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.90% (Net Income -65.6m / Total Assets 131.9m)
RoE = -46.62% (Net Income TTM -65.6m / Total Stockholder Equity 140.7m)
RoCE = -49.17% (EBIT -69.5m / Capital Employed (Equity 140.7m + L.T.Debt 616.0k))
RoIC = -44.39% (negative operating profit) (NOPAT -64.8m / Invested Capital 146.0m)
WACC = 8.54% (E(388.2m)/V(388.8m) * Re(8.55%) + (debt cost/tax rate unavailable))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.35%
[DCF Debug] Terminal Value 76.66% ; FCFF base≈17.6m ; Y1≈18.2m ; Y5≈20.5m
Fair Price DCF = 17.61 (EV 324.5m - Net Debt -30.2m = Equity 354.8m / Shares 20.1m; r=8.54% [WACC]; 5y FCF grow 3.39% → 2.90% )
EPS Correlation: -30.63 | EPS CAGR: -17.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 74.81 | Revenue CAGR: 4.51% | SUE: -0.89 | # QB: 0
EPS next Quarter (2026-02-28): EPS=0.28 | Chg30d=-0.003 | Revisions Net=+0 | Analysts=6
EPS current Year (2026-08-31): EPS=1.02 | Chg30d=+0.015 | Revisions Net=+1 | Growth EPS=-1.3% | Growth Revenue=+1.5%
EPS next Year (2027-08-31): EPS=1.10 | Chg30d=+0.022 | Revisions Net=+0 | Growth EPS=+8.4% | Growth Revenue=+6.7%
Additional Sources for SLP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle